The candidate will be a key contributor to a scientific research team developing cutting edge assay methodology for neurodegenerative protein targets. Responsibilities include development of analytical methodology for characterization of oligomeric proteins implicated in neurodegeneration, protein production for screening execution, statistical data analysis, studies of compound mechanism of action, and assay development. Candidate will work with internal team members, contribute to scientific publications and NIH grant applications, and academic collaborators and travel to scientific meetings to present company results.
What You’ll Bring
Ph.D. in biochemistry plus 5 years experience (industry experience a plus)
Background in neurobiology, pharmacology and biochemistry of target proteins implicated in neurodegeneration
Technical expertise in quantitative protein biochemistry techniques (e.g., Westerns and gel filtration) and cell culture techniques
Excellent teamwork, communication, and analytical skills
About Cognition Therapeutics
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class, orally available small molecule that is currently in clinical trials in patients with mild-to-moderate Alzheimer’s disease. This highly brain penetrant compound targets the sigma-2/PGRMC1 receptor complex, displacing toxic beta amyloid oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. Additional information about Cognition may be found online at http://www.cogrx.com.